metformin has been researched along with Irritable Bowel Syndrome in 6 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Irritable Bowel Syndrome: A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin attenuated the visceral allodynia and increased gut permeability in animal IBS models." | 7.91 | Metformin inhibits visceral allodynia and increased gut permeability induced by stress in rats. ( Kumei, S; Miyagishi, S; Nozu, R; Nozu, T; Okumura, T; Takakusaki, K, 2019) |
| "Metformin was reported to improve these gastrointestinal (GI) changes." | 5.91 | Imeglimin prevents visceral hypersensitivity and colonic hyperpermeability in irritable bowel syndrome rat model. ( Ishioh, M; Miyagishi, S; Nozu, T; Okumura, T; Takakusaki, K, 2023) |
| "Metformin attenuated the visceral allodynia and increased gut permeability in animal IBS models." | 3.91 | Metformin inhibits visceral allodynia and increased gut permeability induced by stress in rats. ( Kumei, S; Miyagishi, S; Nozu, R; Nozu, T; Okumura, T; Takakusaki, K, 2019) |
| "Drug-induced gastrointestinal disorders can mimic conditions, such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and, hence, recognition can prevent unnecessary investigations and treatment." | 2.50 | Drug-induced gastrointestinal disorders. ( Gibson, PR; Lubel, J; Nandurkar, S; Philpott, HL, 2014) |
| "Metformin was reported to improve these gastrointestinal (GI) changes." | 1.91 | Imeglimin prevents visceral hypersensitivity and colonic hyperpermeability in irritable bowel syndrome rat model. ( Ishioh, M; Miyagishi, S; Nozu, T; Okumura, T; Takakusaki, K, 2023) |
| "Metformin pretreatment (a) reduced visceral hypersensitivity to colorectal distension, immobility time and enhanced sucrose consumption; (b) decreased urine lactulose/mannitol ratio and sucralose output; (c) inhibited the dilation of tight junction and prevented claudin-4 translocation; (d) inhibited mast cell activation and downregulated the expression of IL-6, IL-18, tryptase, PAR-2, and ERK activation; (e) inhibited claudin-4 phosphorylation at serine sites and interactions between clau-4 and ZO-1." | 1.51 | Metformin prevents colonic barrier dysfunction by inhibiting mast cell activation in maternal separation-induced IBS-like rats. ( Fang, E; Li, S; Li, W; Li, Y; Liu, C; Yang, T; Yao, Q, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nozu, T | 2 |
| Miyagishi, S | 2 |
| Ishioh, M | 1 |
| Takakusaki, K | 2 |
| Okumura, T | 2 |
| Vich Vila, A | 1 |
| Collij, V | 1 |
| Sanna, S | 1 |
| Sinha, T | 1 |
| Imhann, F | 1 |
| Bourgonje, AR | 1 |
| Mujagic, Z | 1 |
| Jonkers, DMAE | 1 |
| Masclee, AAM | 1 |
| Fu, J | 1 |
| Kurilshikov, A | 1 |
| Wijmenga, C | 1 |
| Zhernakova, A | 1 |
| Weersma, RK | 1 |
| Bahlouli, W | 1 |
| Breton, J | 1 |
| Lelouard, M | 1 |
| L'Huillier, C | 1 |
| Tirelle, P | 1 |
| Salameh, E | 1 |
| Amamou, A | 1 |
| Atmani, K | 1 |
| Goichon, A | 1 |
| Bôle-Feysot, C | 1 |
| Ducrotté, P | 1 |
| Ribet, D | 1 |
| Déchelotte, P | 1 |
| Coëffier, M | 1 |
| Kumei, S | 1 |
| Nozu, R | 1 |
| Li, Y | 2 |
| Yang, T | 1 |
| Yao, Q | 1 |
| Li, S | 1 |
| Fang, E | 1 |
| Liu, C | 1 |
| Li, W | 1 |
| Philpott, HL | 1 |
| Nandurkar, S | 1 |
| Lubel, J | 1 |
| Gibson, PR | 1 |
1 review available for metformin and Irritable Bowel Syndrome
| Article | Year |
|---|---|
Drug-induced gastrointestinal disorders.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antipsychotic Agents; Drug Administr | 2014 |
5 other studies available for metformin and Irritable Bowel Syndrome
| Article | Year |
|---|---|
Imeglimin prevents visceral hypersensitivity and colonic hyperpermeability in irritable bowel syndrome rat model.
Topics: Animals; Colon; Corticotropin-Releasing Hormone; Irritable Bowel Syndrome; Metformin; Rats | 2023 |
Impact of commonly used drugs on the composition and metabolic function of the gut microbiota.
Topics: Adult; Anti-Bacterial Agents; Antidepressive Agents; Bacteria; Body Mass Index; Case-Control Studies | 2020 |
Stress-induced intestinal barrier dysfunction is exacerbated during diet-induced obesity.
Topics: Animals; Cecum; Colon; Corticosterone; Diet, High-Fat; Gastrointestinal Microbiome; Humans; Hypoglyc | 2020 |
Metformin inhibits visceral allodynia and increased gut permeability induced by stress in rats.
Topics: AMP-Activated Protein Kinases; Animals; Colon; Disease Models, Animal; Domperidone; Dopamine Antagon | 2019 |
Metformin prevents colonic barrier dysfunction by inhibiting mast cell activation in maternal separation-induced IBS-like rats.
Topics: Animals; Disease Models, Animal; Hypoglycemic Agents; Intestinal Mucosa; Irritable Bowel Syndrome; M | 2019 |